{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:44:42Z","timestamp":1793043882535,"version":"4.5.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>This article reviews and interprets studies on adjuvant treatment of endometrial cancer published during the last 18 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>For patients with intermediate and high intermediate risk endometrial cancer, vaginal brachytherapy remains the adjuvant therapy of choice. New molecular markers might help to define patients in this group for whom observation only is sufficient and women who might have benefitted from external beam radiotherapy. Preliminary results from large randomized controlled trials have shown that in early stage, high-risk endometrial cancer the addition of chemotherapy to external beam radiotherapy (EBRT) did not improve survival. The combination of vaginal brachytherapy with three courses of chemotherapy resulted in similar progression-free and overall survival (3 years) as EBRT. In stage III high-risk endometrial cancer, the addition of chemotherapy to EBRT improved failure-free survival but not overall survival (immature data). Chemotherapy alone had the same efficacy concerning progression-free and overall survival (immature data).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Three large randomized clinical trials on the role of adjuvant radio and\/or chemotherapy have so far provided only immature results. Discussions about changes of clinical practice should be postponed until mature data from all three trials are available. The impact of new molecular markers for risk stratification will be assessed in ongoing RCTs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000558","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T22:15:00Z","timestamp":1561500900000},"page":"404-410","source":"Crossref","is-referenced-by-count":26,"title":["Adjuvant treatment for endometrial cancer"],"prefix":"10.1097","volume":"31","author":[{"given":"G\u00fcnter","family":"Emons","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, Georg-August-University, G\u00f6ttingen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Vordermark","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Martin-Luther-University, Halle-Wittenberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231206","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA"},{"issue":"(2 Suppl)","key":"R3-20231206","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ijgo.12612","article-title":"Cancer of the corpus uteri","volume":"143","author":"Amant","year":"2018","journal-title":"Int J Gynecol Obstet"},{"key":"R4-20231206","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/GCO.0000000000000506","article-title":"Updates on adjuvant chemotherapy and radiation therapy for endometrial cancer","volume":"31","author":"Cowan","year":"2019","journal-title":"Curr Opin Obstet Gynecol"},{"key":"R5-20231206","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/IGC.0000000000000609","article-title":"ESMO-ESGO-ESTRO consensus conference on endometrial cancer: diagnosis, treatment and follow-up","volume":"26","author":"Colombo","year":"2016","journal-title":"Int J Gyn Cancer"},{"key":"R6-20231206","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Kandoth","year":"2013","journal-title":"Nature"},{"key":"R7-20231206","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/PAS.0000000000001020","article-title":"Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups","volume":"42","author":"Bosse","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R8-20231206","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/annonc\/mdy058","article-title":"Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series","volume":"29","author":"Kommoss","year":"2018","journal-title":"Ann Oncol"},{"key":"R9-20231206","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br J Cancer"},{"issue":"(1 Suppl)","key":"R10-20231206","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1097\/PGP.0000000000000524","article-title":"Pathologic prognostic factors in endometrial carcinoma (other than tumor type and grade)","volume":"38","author":"Singh","year":"2019","journal-title":"Int J Gynecol Pathol"},{"key":"R11-20231206","doi-asserted-by":"crossref","first-page":"329.e1","DOI":"10.1016\/j.ajog.2017.11.601","article-title":"Prognosis and treatment of positive peritoneal cytology in early endometrial cancer: matched cohort analyses from the National Cancer Database","volume":"218","author":"Seagle","year":"2018","journal-title":"Am J Obstet Gynecol"},{"key":"R12-20231206","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/s41416-018-0310-8","article-title":"Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma: improving patient selection for adjuvant therapy","volume":"119","author":"Wortman","year":"2018","journal-title":"Br J Cancer"},{"key":"R13-20231206","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.radonc.2016.12.003","article-title":"Improved overall survival with adjuvant radiotherapy for high-intermediate and high risk stage I endometrial cancer","volume":"122","author":"Harkenrider","year":"2017","journal-title":"Radiother Oncol"},{"key":"R14-20231206","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ygyno.2018.08.028","article-title":"Improved survival with adjuvant brachytherapy in stage IA endometrial cancer of unfavorable histology","volume":"151","author":"Shinde","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R15-20231206","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.brachy.2017.10.011","article-title":"The impact of adjuvant vaginal brachytherapy in women with stage II uterine endometrioid carcinoma: results of a National Cancer Database analysis","volume":"17","author":"Lee","year":"2018","journal-title":"Brachytherapy"},{"key":"R16-20231206","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.brachy.2017.11.001","article-title":"Radiation therapy improves disease-specific survival in women with stage II endometrioid endometrial cancer: brachytherapy may be sufficient","volume":"17","author":"Nwachukwu","year":"2018","journal-title":"Brachytherapy"},{"key":"R17-20231206","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1097\/IGC.0000000000001095","article-title":"Adjuvant therapy use and survival in stage II endometrial cancer","volume":"27","author":"Lester-Coll","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R18-20231206","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ygyno.2018.03.002","article-title":"The role of adjuvant therapy in stage IA serous and clear cell uterine cancer: a multiinstitutional pooled analysis","volume":"149","author":"Qu","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R19-20231206","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1097\/IGC.0000000000000963","article-title":"The addition of adjuvant chemotherapy to radiation in early-stage high-risk endometrial cancer: survival outcomes and patterns of care","volume":"27","author":"Boothe","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"R20-20231206","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ygyno.2017.11.010","article-title":"Adjuvant therapy in patients with clear cell endometrial carcinoma: an analysis of the National Cancer Database","volume":"148","author":"Nieto","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R21-20231206","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ygyno.2018.12.007","article-title":"National patterns of care and cancer-specific outcomes of adjuvant treatment in patients with serous and clear cell endometrial carcinoma","volume":"152","author":"Xiang","year":"2019","journal-title":"Gynecol Oncol"},{"key":"R22-20231206","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.ijrobp.2016.12.035","article-title":"Brachytherapy improves survival in stage III endometrial cancer with cervical involvement","volume":"97","author":"Bingham","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R23-20231206","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ygyno.2018.02.022","article-title":"Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy","volume":"149","author":"Tortorella","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R24-20231206","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/IGC.0000000000001162","article-title":"What is the optimal adjuvant treatment sequence for node-positive endometrial cancer? Results of a national cancer database analysis","volume":"28","author":"Modh","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R25-20231206","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1159\/000488531","article-title":"Lymphadenectomy and adjuvant therapy improve survival with uterine carcinosarcoma: a large retrospective cohort study","volume":"95","author":"Versluis","year":"2018","journal-title":"Oncology"},{"key":"R26-20231206","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S1470-2045(18)30079-2","article-title":"Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial","volume":"19","author":"de Boer","year":"2018","journal-title":"Lancet Oncol"},{"key":"R27-20231206","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1093\/annonc\/mdx753","article-title":"Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer","volume":"29","author":"de Boer","year":"2018","journal-title":"Ann Oncol"},{"key":"R28-20231206","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.ijrobp.2017.09.008","article-title":"A phase 3 trial of pelvic radiation therapy versus vaginal cuff brachytherapy followed by paclitaxel\/carboplatin chemotherapy in patients with high-risk, early-stage endometrial cancer: a gynecology oncology group study","volume":"99","author":"Randall","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"(15 Suppl)","key":"R29-20231206","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1200\/JCO.2017.35.15_suppl.5505","article-title":"A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma","volume":"35","author":"Matei","year":"2017","journal-title":"J Clin Oncol"},{"key":"R30-20231206","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ygyno.2018.05.018","article-title":"A phase II study of frontline paclitaxel\/carboplatin\/bevacizumab, paclitaxel\/carboplatin\/temsirolimus, or ixabepilone\/carboplatin\/bevacizumab in advanced\/recurrent endometrial cancer","volume":"150","author":"Aghajanian","year":"2018","journal-title":"Gynecol Oncol"},{"key":"R31-20231206","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","volume":"36","author":"Fader","year":"2018","journal-title":"J Clin Oncol"},{"key":"R33-20231206","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1200\/JCO.2017.72.5952","article-title":"Safety and antitumor activity of pembrolizumab in advanced programmed death ligand 1-positive endometrial cancer: results from the KEYNOTE-028 study","volume":"35","author":"Ott","year":"2017","journal-title":"J Clin Oncol"},{"key":"R34-20231206","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1158\/1078-0432.CCR-18-3241","article-title":"Molecular subtype not immune response drives outcomes in endometrial carcinoma","volume":"25","author":"Talhouk","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T10:02:40Z","timestamp":1701856960000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000558","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}